Raisio publishes its Financial Statements Bulletin for 2025 on 11 February 2026

Raisio plc will publish its Financial Statements Bulletin for 2025 on 11 February 2026 at approximately 08:30 EET and will hold a Finnish-language webcast for analysts, investors and media at 12:00 EET hosted by CEO Pasi Flinkman and CFO Mika Saarinen; recording and English slides will be made available afterwards. As context, Raisio reported comparable net sales for continuing operations of EUR 226.8 million and comparable EBIT of EUR 23.4 million for 2024, and its shares trade on Nasdaq Helsinki.

Analysis

Market structure: Raisio (group sales €226.8m, comparable EBIT €23.4m in 2024) sits in a niche functional-foods segment where winners are premium-brand owners (Benecol, Elovena) and upstream oat/wheat suppliers if consumer demand holds; losers are undifferentiated private-label cereal/grain processors and margin-sensitive co-packers. The Feb 11 2026 Financials Bulletin + webcast is a liquidity event that can re-price a small-cap premium; a positive beat or upgraded guidance could lift shares 15–30% given low free-float and brand licensing optionality, while a weak guide compresses multiple by 10–20% as peers re-rate multiples for staples.

Risk assessment: Immediate (days) risk is an earnings miss or unclear guidance on Benecol licensing that triggers >10% outflow; short-term (weeks) risks include raw-material cost shocks (oats/wheat spike +10–20%) and EUR FX moves affecting export margins across 40+ markets; long-term tail risks include regulatory changes to health claims for cholesterol-lowering products (royalty decline >30%) or a strategic bid/asset-sale process that alters capital structure. Hidden dependencies: recurring royalty and licence income, retail promotional timing, and concentration in a few export markets – a single distributor dispute could cut reported sales by mid-single digits.

Trade implications: Direct play — establish a tactical 2–3% long position in Raisio (small-cap Nordic food) ahead of Feb 11 if implied 3-day option move is <8% (buy stock or long-dated call spread); set stop at -12% and take-profit at +25% within 6–12 months if guidance improves by ≥100–200bps EBIT margin. Pair trade — long Raisio vs short Orkla (ORK.OL) 1:1 exposure for 3–6 months to isolate niche-brand re-rating vs diversified consumer staples; expect relative outperformance if Raisio reports margin recovery. Options — if implied volatility for Feb 11 is <historical 30-day realized, buy a Jan-15 to Mar-15 call debit spread (defined risk) or a short-dated straddle only if premium <2.5% of market cap-equivalent move.

Contrarian angles: Consensus will treat this as a routine small-cap earnings release; the market may underprice Benecol’s IP/royalty cashflows — a modest upward revision in licensing could justify a 20–40% rerating. Conversely, investor focus on top-line growth ignores potential margin tailwind from cost-savings or SKU rationalization; historical parallels include specialty food re-ratings following clearer margin guidance (e.g., oat-based brands revalued after category consolidation). Unintended consequence: a stronger-than-expected report could attract strategic buyers, forcing a takeover premium but also bidding speculation-driven volatility.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Raisio plc ahead of the Feb 11 results if the 3-day implied move priced by options is <8%; use a protective stop-loss at -12% and plan to trim to half at +15% and exit fully at +25% within 6–12 months if management upgrades EBIT margin by ≥100–200bps.
• Implement a 3–6 month pair trade: long Raisio vs short Orkla (ORK.OL) equal notional to express a bet on niche-brand re-rating; reduce or reverse if Raisio misses guidance or Orkla issues company-specific positive catalysts.
• If options IV is attractive (Feb 11 straddle cost <2.5% of market cap-equivalent expected move), buy a defined-risk call debit spread (strike ladder 5–15% OTM, Jan–Mar expiries) sized to 1–2% portfolio risk; avoid selling premium into unknown regulatory headlines for Benecol.
• Monitor three specific catalysts in next 30–90 days before adding size: (1) Feb 11 webcast guidance on Benecol licensing/revenue split, (2) commodity oat/wheat price moves >+10% which compresses gross margin, and (3) any disclosure of distributor concentration (top-3 export partners >30% sales) — increase or cut exposure based on these thresholds.